Searchable abstracts of presentations at key conferences in endocrinology

ea0070ap1biog | The Geoffrey Harris Prize Lecture | ECE2020

ESE Geoffrey Harris Prize 2020 – Biography

Colao Annamaria

Authored 500+ peer reviewed publications. Her current areas of research include molecular basis and clinical treatment of tumors in the region of the hypothalamus-pituitary and neuroendocrine tumors. Consequences of deficiency and excess of GH and IGF-I on the cardiovascular system. Endocrine consequences in survivors of malignant neoplasia. Insulin resistance and cancer. Secondary osteoporosis. Endocrine consequences of bariatric surgery in obesity. She is affiliated with num...

ea0020s21.3 | Current problems in the management of pituitary tumours | ECE2009

Treatment and prognosis of non-functioning pituitary adenomas

Colao Annamaria

Surgery is the first-line treatment of patients with clinically non-functioning pituitary adenomas (NFA). Because of lack of clinical syndrome these tumours are diagnosed with a variable delay when patients suffer from compression symptoms (hypopituitarism, headache, visual field defects) due to the extension of the tumour outside the pituitary fossa. Surgery is followed by residual tumour tissue in most patients. In these cases, radiotherapy is generally used to prevent tumou...

ea0013s4 | Society for Endocrinology European Medal Lecture | SFEBES2007

GH/IGF-I and the cardiovascular system

Colao Annamaria

Recent epidemiological evidence suggests that low-normal levels of serum IGF-I are associated with increased risk of acute myocardial infarction, ischemic heart disease, coronary and carotid artery atherosclerosis.The IGF-I system is involved in the regulation of cardiovascular physiopathology: it has a physiological role in regulating glucose, protein and lipid metabolism, and in promoting proliferation, differentiation and migration of many cell types....

ea0077lb47 | Late Breaking | SFEBES2021

Evening Chronotype and type 2 diabetes: what link in menopause?

Barrea Luigi , Vetrani Claudia , Verde Ludovica , Savastano Silvia , Colao Annamaria , Muscogiuri Giovanna

Chronotype is defined as a trait determining the subject circadian preference in behavioral and biological rhythms relative to external light-dark cycle.The morning chronotype (MC) prefers activities earlier in the day, while the evening chronotype (EC) perform its main activity late in the day. Intermediate chronotype (IC) is in an intermediate position between MC and EC. EC as well as menopause have been associated to an increased risk of cardiometabolic diseases (CMD) in ob...

ea0081p97 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Chronotype: a tool to screen eating habits in Polycystic Ovary Syndrome?

Verde Ludovica , Barrea Luigi , Vetrani Claudia , Savastano Silvia , Colao Annamaria , Muscogiuri Giovanna

Background: Polycystic Ovary syndrome (PCOS) is the most common endocrine disorders in women of reproductive age whose lifestyle approach is an essential part of the treatment. Recently chronotype, i.e. a trait that determines individual’s circadian preference in behavioral and biological rhythms, has been reported to play a role in determining nutrition preferences and the risk of developing chronic diseases. Thus, the aim of the study was to investigate if chronotype ca...

ea0081p98 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

VLCKD: a real time safety study in obesity

Verde Ludovica , Barrea Luigi , Vetrani Claudia , Marino Francesca , Aprano Sara , Savastano Silvia , Colao Annamaria , Muscogiuri Giovanna

Very Low-Calorie Ketogenic Diet (VLCKD) is currently a promising approach for the treatment of obesity. However, little is known about the side effects since most of the studies reporting them were carried out in normal weight subjects following ketogenic diet for other purposes than obesity. Thus, the aims of the study were: 1) to investigate the safety of VLCKD in subjects with obesity; 2) if VLCKD-related side effects could have an impact on its efficacy. In this prospectiv...

ea0081p667 | Pituitary and Neuroendocrinology | ECE2022

Pituitary adenoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: a single-center study

Modica Roberta , Liccardi Alessia , Minotta Roberto , Cannavale Giuseppe , Benevento Elio , Colao Annamaria

Background: Multiple endocrine neoplasia type 1 (MEN1), is an autosomal dominant inherited disorder with high penentrance, characterized by the onset of multiple tumors, mainly in parathyroid, pituitary gland and gastroenteropancreatic tract. During the course of the disease pituitary adenomas (PA) occur in 20-65%, rarely as first clinical manifestation, and are often described as larger, more aggressive, and more resistant to conventional therapy than their sporadic counterpa...

ea0081p679 | Pituitary and Neuroendocrinology | ECE2022

Efficacy, safety and metabolic impact of long-term pegvisomant therapy in acromegaly: results from a 10-year single center experience

Pirchio Rosa , Simona Auriemma Renata , Elena Montini Maria , Vergura Alice , Pivonello Rosario , Colao Annamaria

Pegvisomant (PEG) is effective in acromegaly control and exerts a positive impact on glucose metabolism. The current study aimed at investigating the effects of 10-years PEG treatment on disease control, pituitary adenoma size, and metabolic profile in patients with acromegaly resistant to somatostatin analogues (SRLs). Twenty-two patients (9 men,13 women, age 45.54 ± 12.83 years) treated with PEG for 10 years, in monotherapy or in combination with SRLs, were included in ...

ea0081p680 | Pituitary and Neuroendocrinology | ECE2022

Long-term pasireotide therapy: real life experience of a single referral center

Pirchio Rosa , Vergura Alice , Elena Montini Maria , Simona Auriemma Renata , Pivonello Rosario , Colao Annamaria

Pasireotide is a second-line therapy for acromegaly, that allows to obtain disease control in patients previously uncontrolled. However, pasireotide-induced hyperglycemia is of major concern. Currently, few data concerning prolonged use of pasireotide are available. The current retrospective study aimed at investigating the efficacy and safety of long-term pasireotide therapy. Sixteen consecutive patients (5 males, 11 females, age 47 ± 11 years) undergoing pasireotide for...

ea0063gp57 | Acromegaly and GH | ECE2019

Biochemical control was sustained with long-acting pasireotide in patients with uncontrolled acromegaly over continued treatment with first-generation somatostatin analogues (SSAs): Results from the extension of phase 3b, open-label study

Gadelha Monica , Colao Annamaria , Bex Marie , Mukherjee Rishav , Bourad Catherine , Maamari Ricardo , Raverot Gerald

Background: In a phase 3b, open-label study (NCT02354508) assessing efficacy and safety of long-acting pasireotide in patients with uncontrolled acromegaly after ≥3 months of treatment with first-generation SSAs, 18/123 (15%) patients achieved the primary endpoint of mean growth hormone (mGH) <1.0 μg/l and insulin-like growth factor-1 (IGF-1) <ULN (upper limit of normal) at week 36. Here, we present the results from the extension phase of this study.<p c...